• Case Discussions: Individualizing Care of Patients with CLL/SLL
- Key Variables in Making Treatment Decisions
- Classes of Agents: Mechanism of Action, Selectivity, Specificity and Associated Adverse Events
- Recent Data on Advances in the Treatment of CLL/SLL
- Optimal and effective management of CLL/SLL
• Partnering With Patients in Their Care
- Discussing Patient Treatment Goals and Expectations
- Best Practices in Patient Care
- Effective Communication of New or Worsening Symptoms with Healthcare Professionals
• Final Thoughts and Audience Question and Answer Session
Date / Time
Jennifer Brown, MD, PhD
Worthington & Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Director and Institute Physician, CLL Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Jeff Sharman, MD
Medical Director of Hematology Research
Willamette Valley Cancer Institute
This program will provide expert perspectives to facilitate state-of-the-art clinical management strategies for patients with CLL/SLL, including information on the latest practice impacting data on recent advances in the personalization of care for patients with CLL/SLL.
The goal of this program is to improve the knowledge, confidence, and competence of multidisciplinary team learners in the care of patients with CLL using evidence-based and guideline-directed best practices.
This program is intended for community-based medical hematologists/oncologists, nurses, pharmacists, advanced practice providers, and other healthcare professionals involved in the treatment of patients with CLL.
Upon completion of this activity, participants should be able to:
- Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration available clinical data, the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference
- Appraise the differences in selectivity, binding, efficacy, and adverse event profiles of agents with a similar molecular target used to treat CLL/SLL
- Develop multidisciplinary management plans for patients with CLL/SLL to optimize quality of life and address racial-related and age-related disparities in care
- Manage treatment-related symptoms in patients with CLL/SLL using guidelines and expert recommendations based on real-world experience to optimally adjust, discontinue, or change the patient’s current therapeutic plan
- Evaluate the evolving role of measurable/minimal residual disease, allogeneic hematopoietic cell transplant, CAR T-cell therapy, and other novel therapeutics for CLL/SLL
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-012-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.